

Please join us for a speaker program

The Role of Collagenase SANTYL® Ointment in Chronic Wound Debridement

SANTYL® Ointment is the only FDA-approved enzymatic debrider that selectively removes necrotic tissue without harming granulation tissue.

Speaker: Aaron Blom, DO, MBA, PLLC
Chester Springs, PA

Location: Cork & Cap
480 New Holland Avenue, Suite #3000 Lancaster, PA 17602

Date: Thursday, March 20, 2014
6:30 PM

This discussion will cover:

- » The role of inflammation in chronic wounds
- » Enzymatic debridement in chronic wounds
- » The use of SANTYL® Ointment as an enzymatic debrider

Registration

If you wish to attend, please log on to: www.pharmethod.com/Smith-Nephew/Register
Program ID: 14077

Or call Matt Meyer at 717/385-7995

Indication

- » Collagenase SANTYL® Ointment is indicated for debriding chronic dermal ulcers and severely burned areas.

Important Safety Information

- » Occasional slight transient erythema has been noted in surrounding tissue when applied outside the wound.
- » One case of systemic hypersensitivity has been reported after 1 year of treatment with collagenase and cortisone.
- » Use of Collagenase SANTYL® Ointment should be terminated when debridement is complete and granulation tissue is well established.

Please see attached complete prescribing information for more details.

For more information, please visit www.santyl.com.



©2013 Smith & Nephew, Inc. SANTYL is a registered trademark of Smith & Nephew, Inc. 1-800-441-8227 www.santyl.com TM1629-1113



Collagenase®
Santyl
Ointment 250 units/g

Enzymatically Active • Biologically Selective

Collagenase[®] SANTYL[®]

Ointment 250 units/g

Rx only

DESCRIPTION: Collagenase SANTYL[®] Ointment is a sterile enzymatic debriding ointment which contains 250 collagenase units per gram of white petrolatum USP. The enzyme collagenase is derived from the fermentation by *Clostridium histolyticum*. It possesses the unique ability to digest collagen in necrotic tissue.

CLINICAL PHARMACOLOGY: Since collagen accounts for 75% of the dry weight of skin tissue, the ability of collagenase to digest collagen in the physiological pH and temperature range makes it particularly effective in the removal of debris.¹ Collagenase thus contributes towards the formation of granulation tissue and subsequent epithelialization of dermal ulcers and severely burned areas.^{2,3,4,5,6} Collagen in healthy tissue or in newly formed granulation tissue is not attacked.^{2,3,4,5,7,8} There is no information available on collagenase absorption through skin or its concentration in body fluids associated with therapeutic and/or toxic effects, degree of binding to plasma proteins, degree of uptake by a particular organ or in the fetus, and passage across the blood brain barrier.

INDICATIONS AND USAGE: Collagenase SANTYL[®] Ointment is indicated for debriding chronic dermal ulcers^{2,3,4,5,6,8,9,10,11,12,13,14,15,16,17,18} and severely burned areas.^{3,4,5,7,16,19,20,21}

CONTRAINDICATIONS: Collagenase SANTYL[®] Ointment is contraindicated in patients who have shown local or systemic hypersensitivity to collagenase.

PRECAUTIONS: The optimal pH range of collagenase is 6 to 8. Higher or lower pH conditions will decrease the enzyme's activity and appropriate precautions should be taken. The enzymatic activity is also adversely affected by certain detergents, and heavy metal ions such as mercury and silver which are used in some antiseptics. When it is suspected such materials have been used, the site should be carefully cleansed by repeated washings with normal saline before Collagenase SANTYL[®] Ointment is applied. Soaks containing metal ions or acidic solutions should be avoided because of the metal ion and low pH. Cleansing materials such as Dakin's solution and normal saline are compatible with Collagenase SANTYL[®] Ointment.

Debrided patients should be closely monitored for systemic bacterial infections because of the theoretical possibility that debriding enzymes may increase the risk of bacteremia.

A slight transient erythema has been noted occasionally in the surrounding tissue, particularly when Collagenase SANTYL[®] Ointment was not confined to the wound. Therefore, the ointment should be applied carefully within the area of the wound. Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS: No allergic sensitivity or toxic reactions have been noted in clinical use when used as directed. However, one case of systemic manifestations of hypersensitivity to collagenase in a patient treated for more than one year with a combination of collagenase and cortisone has been reported.

OVERDOSAGE: No systemic or local reaction attributed to overdose has been observed in clinical investigations and clinical use. If deemed necessary the enzyme may be inactivated by washing the area with povidone iodine.

DOSAGE AND ADMINISTRATION: Collagenase SANTYL[®] Ointment should be applied once daily (or more frequently if the dressing becomes soiled, as from incontinence). When clinically indicated, crosshatching thick eschar with a #10 blade allows Collagenase SANTYL[®] Ointment more surface contact with necrotic debris. It is also desirable to remove, with forceps and scissors, as much loosened debris as can be done readily. Use Collagenase SANTYL[®] Ointment in the following manner:

1 – Prior to application the wound should be cleansed of debris and digested material by gently rubbing with a gauze pad saturated with normal saline solution, or with the desired cleansing agent compatible with Collagenase SANTYL[®] Ointment (See **PRECAUTIONS**), followed by a normal saline solution rinse.

2 – Whenever infection is present, it is desirable to use an appropriate topical antibiotic powder. The antibiotic should be applied to the wound prior to the application of Collagenase SANTYL[®] Ointment. Should the infection not respond, therapy with Collagenase SANTYL[®] Ointment should be discontinued until remission of the infection.

3 – Collagenase SANTYL[®] Ointment may be applied directly to the wound or to a sterile gauze pad which is then applied to the wound and properly secured.

4 – Use of Collagenase SANTYL[®] Ointment should be terminated when debridement of necrotic tissue is complete and granulation tissue is well established.

HOW SUPPLIED: Collagenase SANTYL[®] Ointment contains 250 units of collagenase enzyme per gram of white petrolatum USP.

Do not store above 25°C (77°F). Sterility guaranteed until tube is opened.

Collagenase SANTYL[®] Ointment is available in 15 gram and 30 gram tubes.

REFERENCES: 1. Mandl, I., Adv Enzymol. 23:163, 1961. 2. Boxer, A.M., Gottesman, N., Bernstein, H., & Mandl, I., Geriatrics 24:75, 1969. 3. Mazurek, I., Med. Welt 22:150, 1971. 4. Zimmerman, W.E., in "Collagenase," Mandl, I., ed., Gordon & Breach, Science Publishers, New York, 1971, p. 185. 5. Verra, H., & Whittaker, D., Geriatrics 30:53, 1975. 6. Rao, D.B., Sane, P.G., & Georgiev, E.L., J. Am. Geriatrics Soc. 23:22, 1975. 7. Vrabec, R., Moserova, J., Konickova, Z., Behounkova, E., & Blaha, J., J. Hyg. Epidemiol. Microbiol. Immunol. 18:496, 1974. 8. Lippmann, H.I., Arch. Phys. Med. Rehabil. 54:568, 1973. 9. German, F. M., in "Collagenase," Mandl, I., ed., Gordon & Breach, Science Publishers, New York, 1971, p. 165. 10. Haimovici, H. & Strauch, B., in "Collagenase," Mandl, I., ed., Gordon & Breach, Science Publishers, New York, 1971, p. 177. 11. Lee, L.K., & Amburs, J. L., Geriatrics 30:91, 1975. 12. Locke, R.K., & Helfitz, N.M., J. Am. Pod. Assoc. 65:242, 1975. 13. Varma, A.O., Bugatch, E., & German, F.M., Surg. Gynecol. Obstet. 136:281, 1973. 14. Barrett, D., Jr., & Kilbanski, A., Am. J. Nurs. 73:849, 1973. 15. Bardfield, L.A., J. Pod. Ed. 1:41, 1970. 16. Blum, G., Schweiz. Rundschau Med Praxis 62:820, 1973. Abstr. in Dermatology Digest, Feb. 1974, p. 36. 17. Zaruba, F., Letti, A., Brozkova, L., Skrdianova, H., & Krs, V., J. Hyg. Epidemiol. Microbiol. Immunol. 18:489, 1974. 18. Altman, M.I., Goldstein, L., & Horwitz, S., J. Am. Pod. Assoc. 68:11, 1978. 19. Rehn, V.J., Med. Klin. 58:799, 1963. 20. Krauss, H., Koslowski, L., & Zimmermann, W.E., Langenbecks Arch. Klin. Chir. 303:23, 1963. 21. Guenagel, H.H., Med. Klin. 58:442, 1963.

Manufactured by Healthpoint, Ltd.
Fort Worth, Texas 76107
US Gov't License #1885

Marketed by:

HEALTHPOINT[®]
BIOTHERAPEUTICS

1-800-441-8227
Healthpoint Biotherapeutics
Fort Worth, Texas 76107

Distributed by:
DPT Laboratories, Ltd.
San Antonio, Texas 78215

Reorder Nos.
0064-5010-15 (15 g tube)
0064-5010-30 (30 g tube)

© 2012 Healthpoint, Ltd.
SANTYL is a registered trademark of Healthpoint, Ltd.

129945-0812